Skip to main content
Premium Trial:

Request an Annual Quote

LifeSpan Sells GPCR Portfolio to MBL, Plans to Continue Antibody Line

NEW YORK, Feb. 21 (GenomeWeb News) - LifeSpan BioSciences has sold "most of its existing catalog" of antibodies to Medical and Biological Laboratories International, LifeSpan confirmed today.

 

The Massachusetts-based subsidiary of Nagoya, Japan-based MBL bought 921 antibodies to about 400 different protein targets, including 800 GPCR antibodies.

 

"MBL has a broader reach in terms of selling this product," LifeSpan CEO Joseph Brown said.  

 

Brown said LifeSpan plans to continue developing antibodies to gene-target proteins and will consider future distribution deals with MBL.

 

Financial details of the deal were not available.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.